• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Oncotarget: Hyperprogression to immune blockade followed by a response with cabozantinib

Bioengineer by Bioengineer
June 10, 2020
in Health
Reading Time: 4 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Volume 11, Issue 22 of @Oncotarget reported that more and more patients receive first-line treatment with immunotherapy combinations and not all patients respond in metastatic renal cell carcinoma.

IMAGE

Credit: Correspondence to – Javier Molina-Cerrillo – javier.molinace@gmail.com

Volume 11, Issue 22 of @Oncotarget reported that more and more patients receive first-line treatment with immunotherapy combinations and not all patients respond in metastatic renal cell carcinoma.

After IO-IO progression, the authors stated “we do not have a standard of treatment because it is not available for prospective data on this setting.”

Therefore the authors present the case of a patient with metastatic renal cell carcinoma who suffered hyperprogression with IO-IO combination in the first line.

The molecular mechanism to explain patients’ response, its the probably crosstalk between MET and NOTCH pathway.

Nowadays, there is not clear the subsequent treatment in those patients who progress to IO-IO first line.

More efforts in biomarker development should be made to better selection of patients’ treatment along with the disease.

Dr. Javier Molina-Cerrillo from The Medical Oncology Department, Ramón y Cajal University Hospital in Madrid Spain said “We present the case of a 50-year-old male who came to the emergency room in March 2019 due to the recent appearance of a mass in the lower region of the left thigh.“

Body CT scan revealed the presence of myocardial implants with extension towards the left ventricular lumen measuring up to 50 mm and pericardial implants, micronodules in both lungs, several lesions in the right gluteus, up to 21 mm and a mass in the upper pole of the left kidney of 6.8 5.5 cm.

The radiological assessment confirmed the clinical suspicion of disease progression with an increase in the renal tumor mass of 7.7 5.9 cm, new intraabdominal implants in the right perirenal space of 4 cm, and left of 3 cm, right hypochondrium of 5.5 cm and left iliac fossa of 4 cm.

The patient began this treatment in early June 2019 with close monitoring of adverse events and tumor assessment.

After 2 weeks of treatment, the patient began to experience significant clinical improvement, recovering to a KI of 90% and with an objective tumor reduction of the visible implants in the left dorsolumbar region, right gluteus muscle, and disappearance in the vast intermediate lesion.

“After 2 weeks of treatment, the patient began to experience significant clinical improvement, recovering to a KI of 90% and with an objective tumor reduction of the visible implants in the left dorsolumbar region, right gluteus muscle, and disappearance in the vast intermediate lesion”

Those data show some activity from TKIs in this setting, but in patients not responding to the IO-IO combination, response durations are below 5 months, representing a subgroup of patients with a particularly poor prognosis.

The Molina-Cerrillo Research Team concluded in their Oncotarget Case Report that there may be hyperprogressions with the new combinations in RCC, the NOTCH pathway may be activated in some patients, and MET inhibition may be key to its control.

In this case, it is demonstrated that a TKI such cabozantinib can control hyperprogression phenomena in 2L of m cc RCC. Clinical trials are currently ongoing in this setting trying to elucidate, prospectively, which is the best strategy.

In this sense, biomarker research is essential to identify those tumor profiles that provide information about the best approach in the first-line setting and beyond.

Sign up for free Altmetric alerts about this article

DOI – https://doi.org/10.18632/oncotarget.27598

Full text – https://www.oncotarget.com/article/27598/text/

Correspondence to – Javier Molina-Cerrillo – javier.molinace@gmail.com

Keywords –
immunotherapy,
renal cell carninoma,
cabozantinib,
NOTCH

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud – https://soundcloud.com/oncotarget
Facebook – https://www.facebook.com/Oncotarget/
Twitter – https://twitter.com/oncotarget
LinkedIn – https://www.linkedin.com/company/oncotarget
Pinterest – https://www.pinterest.com/oncotarget/
Reddit – https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
RYAN JAMES
RYANJAMESJESSUP@IMPACTJOURNALS.COM

Original Source

https://www.oncotarget.com/news/pr/hyperprogression-to-immune-blockade-followed-by-a-response-with-cabozantinib/

Related Journal Article

http://dx.doi.org/10.18632/oncotarget.27598

Tags: cancerCarcinogensMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

App-Guided Ear Acupressure Cuts Chronic Musculoskeletal Pain in Pilot Trial

App-Guided Ear Acupressure Cuts Chronic Musculoskeletal Pain in Pilot Trial

November 18, 2026
Decitabine Restores Osimertinib Sensitivity in Resistant Lung Cancer via Autophagy Pathway

Decitabine Restores Osimertinib Sensitivity in Resistant Lung Cancer via Autophagy Pathway

November 18, 2026

Cumulative Vascular Compromise Drives Rare Maxillary Necrosis After Le Fort Osteotomy

November 18, 2026

Off-Hour Births in African Hospitals Linked to Increased Early Neonatal Mortality Risk

November 18, 2026
Please login to join discussion

POPULAR NEWS

  • Spain NTD Drug Study Reveals Severe Territorial Gaps Across Autonomous Communities

    Spain NTD Drug Study Reveals Severe Territorial Gaps Across Autonomous Communities

    29 shares
    Share 12 Tweet 7
  • Guinea Health Study Reveals Severe Workforce Unemployment Despite Rising Professional Training

    29 shares
    Share 12 Tweet 7
  • Rootstock Signaling Networks Dynamically Reprogram Fruit Quality Across Horticultural Crops

    29 shares
    Share 12 Tweet 7
  • Review Uncovers How Group 2 Innate Lymphoid Cells Bridge Neuroimmune Communication

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Structural Modifications Shield High-Temperature Carbon Foams Against Rapid Oxidation Failure

Spinal Cord Injury Index Tracks Intraoperative Trauma During Spinal Cord Tumor Resection

App-Guided Ear Acupressure Cuts Chronic Musculoskeletal Pain in Pilot Trial

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.